Wellington Management Group LLP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Wellington Management Group LLP purchased a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 60,751 shares of the biotechnology company’s stock, valued at approximately $546,000.

A number of other large investors have also recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at about $25,000. GF Fund Management CO. LTD. bought a new stake in Aurinia Pharmaceuticals in the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC lifted its stake in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $31,000. Finally, Natixis bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $49,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock opened at $8.19 on Friday. The business has a 50-day simple moving average of $7.95 and a 200 day simple moving average of $8.26. Aurinia Pharmaceuticals Inc. has a one year low of $5.15 and a one year high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -54.60 and a beta of 1.15.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The firm had revenue of $62.47 million during the quarter, compared to analysts’ expectations of $61.06 million. On average, research analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.